Vascular Biogenics Ltd (VBLT)

[davidal66]

Yes, '16. If you look carefully at the VB-111 continuous exposure cohort and throw out the folks who succumb to the disease right away and also throw away the complete response, you basically see better control of the tumor than Avastin alone.... i.e., stabilized response for longer periods of time. Another crucial concept that I believe may apply here(and completely unrecognized by the pundits on twitter)is the concept of survival after progression. In certain cancers, an an agent may be dismissed as a failure since progression free survival is not prolonged and patient's progress but they live longer and so the agent increases the so-called survival after progression period. It is a fascinating topic that I may post here with some links later. A final point that is fascinating. If you look at some of the immune therapies against lung cancers in the early trials, it looked like the checkpoint compounds had poorer progression survival than SOC, but they lived longer so overall survival advantage to checkpoint inhibitors. Talk about a group of fascinating paradoxes.